Ascendis Pharma Presents at Morgan Stanley Global Healthcare Conference Tuesday Following ESPE 2026 reACHin Week 52 Infant Data + Wells Fargo Franchise Update
Ascendis Pharma A/S (NASDAQ: ASND) presented Tuesday September 15, 2026 at 8:30 a.m. ET at the Morgan Stanley 24th Annual Global Healthcare Conference in New York in a fireside chat format. The presentation followed the ESPE 2026 congress podium delivery September 8 of first Week 52 sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP, marketed as YUVIWEL in the U.S.) in 7 infants with achondroplasia aged 0 to under 2 years: 9.9 cm/year annualized growth velocity, +0.42 ACH-specific supine length Z-score, +3.15 mm sagittal foramen magnum increase, and no decompression surgeries at 100 μg/kg/week dosing. The Ascendis TransCon endocrinology franchise reached €315 million in combined Q2 2026 product revenue (+105% year-over-year): YORVIPATH (palopegteriparatide, PTH replacement) €252 million, SKYTROFA (lonapegsomatropin, growth hormone) €55 million, and YUVIWEL (navepegritide, CNP for achondroplasia) €8 million in the first U.S. commercial quarter. The August 31 Ascendis-BioMarin global settlement resolves the YUVIWEL patent overhang (20% U.S. royalties, 18% EU/South Korea/Brazil through May 2030; ITC Section 337 dismissed).